ZYZhiping Yuan

Zhiping Yuan

*This is an algorithmically generated author record based on publicly available information.

Zhiping Yuan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Ao Shen

    Departments of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    1 shared publication
  • Chang-Ping Wang

    Department of Oncology, The First People’s Hospital of Yibin, Yibin, China

    1 shared publication
  • Changping Wang

    Department of Oncology, The First People's Hospital of Yibin, Yibin, 644000, Sichuan, China, 65 Wenxing Street

    1 shared publication
  • Chuan Lin

    Department of Oncology, The First People’s Hospital of Yibin, Yibin, China

    1 shared publication
  • Chuan Lin

    Department of Oncology, The First People's Hospital of Yibin, Yibin, 644000, Sichuan, China, 65 Wenxing Street.

    1 shared publication
  • Dan Lei

    Department of Oncology, The First People’s Hospital of Yibin, Yibin, China

    1 shared publication

Latest Publications

  • Open Access

    Nomogram Model Based on Serum Metabolic Biomarkers to Predict Outcomes of First-Line Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer

    by Ting Zeng, Wei Han, Lishuai Wang, Zhiping Yuan

    Background: This study attempted to combine Serum Metabolic Biomarkers with clinical factors to construct nomograms to predict outcomes of patients with advanced non-small cell lung cancer( NSCLC) receiving first-line chemoimmunotherapy (CIT). Methods: A retrospective analysis was conducted on 112 patients with stage IIIC–IVB NSCLC receiving first-line CIT between January 2019 and January 2022.The Serum Metabolic Biomarker including lactate dehydrogenase (LDH), lactate (LAC), uric acid (UA), albumin (ALB), triglycerides (TG) and total cholesterol (TC) were examined at baseline. Patients were stratified into responders (R)and non-responders(NR) based on treatment efficacy. Progression-free survival (PFS) and overall survival (OS) were assessed via Kaplan-Meier analysis. Nomograms was created based on the multivariate Cox regression analysis to predict OS and PFS. The nomogram was internally validated using bootstrap resampling. Nomogram was assessed using the concordance index (C-index), the time-dependent area under the receiver operating curves(ROC), calibration curves, and decision curve analysis (DCA). Results: Non-diabetic status, PD-L1 expression≥50%, low LDH, LAC, UA, TC and high ALB correlated with better response (all PConclusion: Serum metabolic biomarkers (LDH, LAC, UA, ALB, TG) hold significant value in predicting outcomes of chemoimmunotherapy in advanced NSCLC. The nomograms provide accurate and practical tools to guide personalized treatment decisions.

  • Open Access

    Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study

    by Xiaochun Chen, Changping Wang, Yuanjie Tang, Haoyan Sun, Hongling Liu, Chuan Lin, Zhiping Yuan

    This study was designed to assess the safety and efficacy of Sintilimab plus Lenvatinib in combination with transarterial chemoembolization (TACE) and subsequent radiofrequency ablation (RFA) in the treatment of unresectable hepatocellular carcinoma (HCC). A retrospective data analysis was conducted on 21 patients diagnosed with HCC at Yibin First People's Hospital, between February 2021 and July 2022. These patients met the eligibility criteria and underwent TACE followed by RFA. After the first TACE, patients received maintenance therapy with Sintilimab and Lenvatinib until the occurrence of intolerable toxicity, disease progression, or demise. The primary endpoints were progression-free survival (PFS) and overall survival (OS). The efficacy evaluation revealed a complete response (CR) in 7 patients (33.33%), a partial response (PR) in 13 (61.91%), and a stable disease (SD) in 1 (4.76%). The patients had a median follow-up duration of 29.4 months (95% CI, 24.67-34.14), with a median PFS of 17.3 months (95% CI, 5.84-28.76). The median OS was not reached (NR), with a 1-year OS rate of 95.24% and a 2-year OS rate of 75.89%. Tumor recurrence and metastasis occurred in 15 patients (71.43%), oligoprogression in 8 patients (38.90%) and extensive progression in 7 patients (33.33%), which were associated with the median OS duration of NR and 26.03 months (95%CI 17.48-34.59), respectively (P = 0.024). In terms of treatment safety, 95.24% (20 cases) of patients experienced treatment-related adverse events (AEs), mainly mild to moderate severity. Notably, 10 patients (47.62%) encountered at least one grade 3 or higher AEs, leading to treatment discontinuation in 2 patients due to severe side effects. The clinical efficacy and safety of Sintilimab plus Lenvatinib in combination with TACE followed by RFA has been shown to be promising in the treatment of unresectable HCC. These results suggested that this combined treatment strategy may be an effective therapeutic approach. Furthermore, patients with oligoprogression after initial treatment exhibited a more favorable prognosis, indicating a need for further exploration and validation by studies with larger sample sizes.

  • Open Access

    Construction of a prognostic model for gastric cancer based on immune infiltration and microenvironment, and exploration of MEF2C gene function

    by Si-Yu Wang, Yu-Xin Wang, Lu-Shun Guan, Ao Shen, Run-Jie Huang, Shu-Qiang Yuan, Yu-Long Xiao, Li-Shuai Wang, Dan Lei, Yin Zhao, et al.

    Advanced gastric cancer (GC) exhibits a high recurrence rate and a dismal prognosis. Myocyte enhancer factor 2c (MEF2C) was found to contribute to the development of various types of cancer. Therefore, our aim is to develop a prognostic model that predicts the prognosis of GC patients and initially explore the role of MEF2C in immunotherapy for GC. Transcriptome sequence data of GC was obtained from The Cancer Genome Atlas (TCGA), the Gene Expression Omnibus (GEO) and PRJEB25780 cohort for subsequent immune infiltration analysis, immune microenvironment analysis, consensus clustering analysis and feature selection for definition and classification of gene M and N. Principal component analysis (PCA) modeling was performed based on gene M and N for the calculation of immune checkpoint inhibitor (ICI) Score. Then, a Nomogram was constructed and evaluated for predicting the prognosis of GC patients, based on univariate and multivariate Cox regression. Functional enrichment analysis was performed to initially investigate the potential biological mechanisms. Through Genomics of Drug Sensitivity in Cancer (GDSC) dataset, the estimated IC50 values of several chemotherapeutic drugs were calculated. Tumor-related transcription factors (TFs) were retrieved from the Cistrome Cancer database and utilized our model to screen these TFs, and weighted correlation network analysis (WGCNA) was performed to identify transcription factors strongly associated with immunotherapy in GC. Finally, 10 patients with advanced GC were enrolled from Sun Yat-sen University Cancer Center, including paired tumor tissues, paracancerous tissues and peritoneal metastases, for preparing sequencing library, in order to perform external validation. Lower ICI Score was correlated with improved prognosis in both the training and validation cohorts. First, lower mutant-allele tumor heterogeneity (MATH) was associated with lower ICI Score, and those GC patients with lower MATH and lower ICI Score had the best prognosis. Second, regardless of the T or N staging, the low ICI Score group had significantly higher overall survival (OS) compared to the high ICI Score group. For its mechanisms, consistently, for Camptothecin, Doxorubicin, Mitomycin, Docetaxel, Cisplatin, Vinblastine, Sorafenib and Paclitaxel, all of the IC50 values were significantly lower in the low ICI Score group compared to the high ICI Score group. As a result, based on univariate and multivariate Cox regression, ICI Score was considered to be an independent prognostic factor for GC. And our Nomogram showed good agreement between predicted and actual probabilities. Based on CIBERSORT deconvolution analysis, there was difference of immune cell composition found between high and low ICI Score groups, probably affecting the efficacy of immunotherapy. Then, MEF2C, a tumor-related transcription factor, was screened out by WGCNA analysis. Higher MEF2C expression is significantly correlated with a worse OS. Moreover, its higher expression is also negatively correlated with tumor mutation burden (TMB) and microsatellite instability (MSI), but positively correlated with several immunosuppressive molecules, indicating MEF2C may exert its influence on tumor development by upregulating immunosuppressive molecules. Finally, based on transcriptome sequencing data on 10 paired tumor tissues from Sun Yat-sen University Cancer Center, MEF2C expression was significantly lower in paracancerous tissues compared to tumor tissues and peritoneal metastases, and it was also lower in tumor tissues compared to peritoneal metastases, indicating a potential positive association between MEF2C expression and tumor invasiveness. Our prognostic model can effectively predict outcomes and facilitate stratification GC patients, offering valuable insights for clinical decision-making. The identified transcription factor MEF2C can serve as a biomarker for assessing the efficacy of immunotherapy for GC.